Christian Radke1, Dagmar Horn2, Christian Lanckohr3, Björn Ellger3, Michaela Meyer4, Thomas Eissing4, Georg Hempel5. 1. Department of Clinical Pharmacy, Institute of Pharmaceutical and Medical Chemistry, University of Muenster, Corrensstrasse 48, 48149, Muenster, Germany. 2. Department of Pharmacy, University Hospital of Muenster, Muenster, Germany. 3. Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Muenster, Muenster, Germany. 4. Systems Pharmacology CV, Bayer Technology Services GmbH, Leverkusen, Germany. 5. Department of Clinical Pharmacy, Institute of Pharmaceutical and Medical Chemistry, University of Muenster, Corrensstrasse 48, 48149, Muenster, Germany. georg.hempel@uni-muenster.de.
Abstract
BACKGROUND AND OBJECTIVES: Sepsis is characterised by an excessive release of inflammatory mediators substantially affecting body composition and physiology, which can be further affected by intensive care management. Consequently, drug pharmacokinetics can be substantially altered. This study aimed to extend a whole-body physiologically based pharmacokinetic (PBPK) model for healthy adults based on disease-related physiological changes of critically ill septic patients and to evaluate the accuracy of this PBPK model using vancomycin as a clinically relevant drug. METHODS: The literature was searched for relevant information on physiological changes in critically ill patients with sepsis, severe sepsis and septic shock. Consolidated information was incorporated into a validated PBPK vancomycin model for healthy adults. In addition, the model was further individualised based on patient data from a study including ten septic patients treated with intravenous vancomycin. Models were evaluated comparing predicted concentrations with observed patient concentration-time data. RESULTS: The literature-based PBPK model correctly predicted pharmacokinetic changes and observed plasma concentrations especially for the distribution phase as a result of a consideration of interstitial water accumulation. Incorporation of disease-related changes improved the model prediction from 55 to 88% within a threshold of 30% variability of predicted vs. observed concentrations. In particular, the consideration of individualised creatinine clearance data, which were highly variable in this patient population, had an influence on model performance. CONCLUSION: PBPK modelling incorporating literature data and individual patient data is able to correctly predict vancomycin pharmacokinetics in septic patients. This study therefore provides essential key parameters for further development of PBPK models and dose optimisation strategies in critically ill patients with sepsis.
BACKGROUND AND OBJECTIVES:Sepsis is characterised by an excessive release of inflammatory mediators substantially affecting body composition and physiology, which can be further affected by intensive care management. Consequently, drug pharmacokinetics can be substantially altered. This study aimed to extend a whole-body physiologically based pharmacokinetic (PBPK) model for healthy adults based on disease-related physiological changes of critically ill septicpatients and to evaluate the accuracy of this PBPK model using vancomycin as a clinically relevant drug. METHODS: The literature was searched for relevant information on physiological changes in critically illpatients with sepsis, severe sepsis and septic shock. Consolidated information was incorporated into a validated PBPK vancomycin model for healthy adults. In addition, the model was further individualised based on patient data from a study including ten septicpatients treated with intravenous vancomycin. Models were evaluated comparing predicted concentrations with observed patient concentration-time data. RESULTS: The literature-based PBPK model correctly predicted pharmacokinetic changes and observed plasma concentrations especially for the distribution phase as a result of a consideration of interstitial water accumulation. Incorporation of disease-related changes improved the model prediction from 55 to 88% within a threshold of 30% variability of predicted vs. observed concentrations. In particular, the consideration of individualised creatinine clearance data, which were highly variable in this patient population, had an influence on model performance. CONCLUSION: PBPK modelling incorporating literature data and individual patient data is able to correctly predict vancomycin pharmacokinetics in septicpatients. This study therefore provides essential key parameters for further development of PBPK models and dose optimisation strategies in critically illpatients with sepsis.
Authors: Andrea Morelli; Matthias Lange; Christian Ertmer; Martin Dünser; Sebastian Rehberg; Alessandra Bachetoni; Marladomenica D'Alessandro; Hugo Van Aken; Fabio Guarracino; Paolo Pietropaoli; Daniel L Traber; Martin Westphal Journal: Shock Date: 2008-04 Impact factor: 3.454
Authors: Martin G Kees; Sebastian G Wicha; Astrid Seefeld; Frieder Kees; Charlotte Kloft Journal: J Clin Pharmacol Date: 2013-09-21 Impact factor: 3.126
Authors: Giulia Reggiori; Giovanna Occhipinti; Andrea De Gasperi; Jean-Louis Vincent; Michael Piagnerelli Journal: Crit Care Med Date: 2009-12 Impact factor: 7.598
Authors: Andrea Morelli; Monica Rocco; Giorgio Conti; Alessandra Orecchioni; Andrea De Gaetano; Giuliana Cortese; Flaminia Coluzzi; Enrico Vernaglione; Paolo Pelaia; Paolo Pietropaoli Journal: Intensive Care Med Date: 2003-12-12 Impact factor: 17.440
Authors: Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel Journal: PLoS Comput Biol Date: 2019-06-13 Impact factor: 4.475
Authors: Sonja E Zapke; Stefan Willmann; Scott-Oliver Grebe; Kristin Menke; Petra A Thürmann; Sven Schmiedl Journal: Front Pharmacol Date: 2021-05-14 Impact factor: 5.810
Authors: Kevin M Watt; Michael Cohen-Wolkowiez; Jeffrey S Barrett; Michael Sevestre; Ping Zhao; Kim L R Brouwer; Andrea N Edginton Journal: CPT Pharmacometrics Syst Pharmacol Date: 2018-08-13